SARS-CoV-2 infection in a pediatrics STAT1 GOF patient under Ruxolitinib therapy-a matter of balance?

J Clin Immunol. 2021 Oct;41(7):1502-1506. doi: 10.1007/s10875-021-01081-9. Epub 2021 Jun 9.
No abstract available

Publication types

  • Case Reports
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • COVID-19 / genetics
  • COVID-19 / immunology*
  • COVID-19 Drug Treatment
  • Child
  • Female
  • Humans
  • Interferon-Stimulated Gene Factor 3 / genetics*
  • Janus Kinases / antagonists & inhibitors
  • Mutation / genetics*
  • Nitriles
  • Pyrazoles / therapeutic use*
  • Pyrimidines
  • SARS-CoV-2 / physiology*
  • Severity of Illness Index

Substances

  • Interferon-Stimulated Gene Factor 3
  • Nitriles
  • Pyrazoles
  • Pyrimidines
  • gamma interferon activation factor
  • ruxolitinib
  • Janus Kinases